Clinical Research Directory

Inclusion Criteria: * Age ≥ 40 years; * Spontaneous intracerebral hemorrhage (ICH) confirmed by neuroimaging; * Hematoma volume 15-60 mL; * Within 48 hours of symptom onset (if onset time is unknown, the time last seen normal is used); * Meeting one of the following: basal ganglia or lobar hemorrhage with NIHSS score ≥ 8; or thalamic, brainstem or cerebellar hemorrhage with Glasgow Coma Scale (GCS) score 7-14; * Written informed consent obtained from the patient or the legal representative. Exclusion Criteria: * ICH secondary to structural brain abnormalities (including but not limited to cerebral vascular malformation, intracranial aneurysm, malignant tumor, moyamoya disease, trauma and prior ischemic stroke), cerebral amyloid angiopathy, thrombolysis or thrombectomy, anticoagulant therapy, antiplatelet therapy, or other secondary causes; * Patients judged by the responsible physician unlikely to benefit from the trial (e.g., advanced dementia) or at very high risk of early death, or other conditions considered unsuitable by the investigator; * Conditions that may interfere with follow-up or outcome assessment (e.g., significant pre-stroke disability with modified Rankin Scale score 3-5, end-stage malignant tumor, renal failure); * Known contraindications to Chinese medicine; * Pregnancy or breastfeeding; * Participation in another clinical trial that may interfere with the evaluation of this trial.